In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Pyxis Oncology Inc (NASDAQ: PYXS) was $1.19 for the day, down -6.67% from the previous closing price of $1.27. In other words, the price has decreased by -$6.67 from its previous closing price. On the day, 3.1 million shares were traded. PYXS stock price reached its highest trading level at $1.39 during the session, while it also had its lowest trading level at $1.16.
Ratios:
Our analysis of PYXS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.29 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 74094424 and an Enterprise Value of 16911416. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.28 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 5.997 whereas that against EBITDA is -0.21.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.46, which has changed by -0.203125 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.55, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is -69.74%, while the 200-Day Moving Average is calculated to be -40.31%.
Shares Statistics:
PYXS traded an average of 967.09K shares per day over the past three months and 1954320 shares per day over the past ten days. A total of 62.15M shares are outstanding, with a floating share count of 48.09M. Insiders hold about 22.76% of the company’s shares, while institutions hold 38.03% stake in the company. Shares short for PYXS as of 1764288000 were 4523744 with a Short Ratio of 4.68, compared to 1761868800 on 4361521. Therefore, it implies a Short% of Shares Outstanding of 4523744 and a Short% of Float of 8.790000000000001.
Earnings Estimates
The stock of Pyxis Oncology Inc (PYXS) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.23 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.14 and -$1.38 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$1.18, with 8.0 analysts recommending between -$0.79 and -$1.54.
